MD Anderson and RaySearch form alliance to advance radiation therapy

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

MD Anderson Cancer Center and RaySearch Laboratories formed a strategic alliance with the aim of enhancing cancer radiation therapy through several initiatives, including more precisely targeting of tumors and improving upon, and making more available, an existing radiation therapy called adaptive radiation therapy, currently only used at highly specialized care centers.

Traditionally, additional margins are set around the target area to allow for tumor movement and variations in how patients are positioned during treatment.

However, these margins do not always compensate for unexpected changes in the tumor and surrounding normal tissue over the full course of radiation treatment. Adaptive radiation therapy uses frequent imaging to give an up-to-date assessment of physical changes and enable precisely tailored treatment for each patient.

The partnership, which builds upon a previously established relationship between RaySearch and MD Anderson centered on RayCare, RaySearch’s new oncology information system, combines MD Anderson’s clinical data and expertise with the latest technology and platforms available through RaySearch and will focus on the following areas:

  • Integration of advanced imaging into the treatment planning process to help define the tumor targets better.

  • Management of changes in the tumor that may occur during treatment, and monitoring and adjusting treatment to accommodate each patient’s individual circumstances at any point during therapy.

  • Building software components with the aim of creating a new standard of care in radiation therapy.

YOU MAY BE INTERESTED IN

The nagging pain in Mia Sandino’s right knee set in in September 2018, and throughout her freshman year at the University of Washington, she tried to ignore it. “I was being a very naive and invincible-feeling 19-year-old,” Sandino told The Cancer Letter. “I didn’t put two and two together that this area of the knee that...

Rick Pazdur, MD, the newly appointed director for the Center for Drug Evaluation and Research at the FDA, has been described as “greyhound thin” as a result of his dedication to cycling and lifting weights in the gym each day and, for a long time, a vegetarian diet. I first met him when he was the director of the Office of Oncology Drug Products (ODP) within CDER, in 2009.
When it comes to fighting cancer today, collaboration is key. At a time when funding is uncertain, yet innovative breakthroughs are accelerating every day, it’s more important than ever for oncologists, scientists, academic researchers, and community physicians, to come together to share knowledge and gain insights about the forefront of cancer research.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login